(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.37%) $78.40
(0.47%) $2.15
(0.34%) $2 316.50
(2.04%) $27.24
(-0.31%) $962.35
(-0.04%) $0.928
(-0.14%) $10.86
(-0.06%) $0.797
(0.00%) $91.45
Quarter results tomorrow
(amc 2024-05-07)
Expected move: +/- 11.77%
-4.24% $ 0.810
Live Chart Being Loaded With Signals
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 185 552 |
Średni wolumen | 402 749 |
Kapitalizacja rynkowa | 63.28M |
EPS | $-0.220 ( 2024-05-02 ) |
Następna data zysków | ( $-0.190 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.600 |
ATR14 | $0.00900 (1.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Mcclure Matthew W. | Buy | 72 000 | Stock Option (Right to Buy) |
2024-03-01 | Calhoun Lesley Ann | Buy | 308 940 | Stock Option (Right to Buy) |
2024-03-01 | Symons Julian A. | Buy | 72 000 | Stock Option (Right to Buy) |
2024-03-01 | Blatt Lawrence | Buy | 965 435 | Stock Option (Right to Buy) |
2024-02-28 | Hirth Peter | Buy | 4 411 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
82.22 |
Last 96 transactions |
Buy: 18 924 669 | Sell: 1 675 487 |
Wolumen Korelacja
Aligos Therapeutics, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
MCRB | 0.914 |
EIGR | 0.914 |
SPRC | 0.908 |
BTTX | 0.907 |
ENTA | 0.907 |
AFIB | 0.906 |
CYN | 0.906 |
CAMP | 0.905 |
MESA | 0.904 |
GOCO | 0.904 |
10 Najbardziej negatywne korelacje | |
---|---|
GEEX | -0.92 |
FXCO | -0.918 |
LDHA | -0.917 |
NESR | -0.914 |
TCVA | -0.911 |
ALOR | -0.911 |
TBSA | -0.909 |
VLAT | -0.909 |
AHRN | -0.908 |
LGAC | -0.908 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Aligos Therapeutics, Inc. Korelacja - Waluta/Towar
Aligos Therapeutics, Inc. Finanse
Annual | 2023 |
Przychody: | $15.53M |
Zysk brutto: | $12.46M (80.24 %) |
EPS: | $-1.360 |
FY | 2023 |
Przychody: | $15.53M |
Zysk brutto: | $12.46M (80.24 %) |
EPS: | $-1.360 |
FY | 2022 |
Przychody: | $13.91M |
Zysk brutto: | $10.23M (73.57 %) |
EPS: | $-2.25 |
FY | 2021 |
Przychody: | $4.36M |
Zysk brutto: | $4.36M (100.00 %) |
EPS: | $-3.22 |
Financial Reports:
No articles found.
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej